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Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous form of hematological cancer consisting of
various subtypes. We are interested to study the genetic aberration in precursor B-cell ALL with specific t(12;21)
translocation in childhood ALL patients. A high resolution 244K array-based Comparative Genomic Hybridization
(array-CGH) was used to study eleven ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL) patients.
Result: 155 chromosomal aberrations (119 losses, 36 gains) were reported in the array findings, corresponding to
76.8% deletions and 23.2% amplifications. The ETV6 gene deletion occurred in 4 of the patients, corresponding to
45% of the sample. The most common alterations above 1 Mb were deletion 6q (13%), 12p (12%) and 9p (8%), and
duplication 4q (6%) and Xq (4%). Other genes important in ALL were also identified in this study including RUNX1,
CDKN2A, FHIT, and PAX5. The array-CGH technique was able to detect microdeletion as small as 400 bp.
Conclusion: The results demonstrate the usefulness of high resolution array-CGH as a complementary tool in the
investigation of ALL.
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In childhood B-cell precursor acute lymphoblastic leukemia
(ALL), t(12;21)(p13;q22) translocation is the most common
chromosomal abnormality and occurs in 20-25% of the
cases [1]. This reciprocal translocation, which has a favor-
able prognosis of more than 80%, leads to the formation of
the ETV6/RUNX1 (also known as TEL/AML1) fusion gene
[1,2]. The ETV6/RUNX1 fusion gene was reported in 19%
of the Malaysian childhood ALL [3].
Based on the primary ETV6/RUNX1 leukemogenic
model, the translocation arises in utero and the rearrange-
ment alone is not sufficient to develop the disease itself
[4]. Other secondary genetic alterations (or "hits") are
required to trigger the disease progression; however the* Correspondence: zubaidah@imr.gov.my
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reproduction in any medium, provided the orrole of the additional aberrations has not been fully deter-
mined [4]. The secondary events such as copy number
alterations and point mutations have been suggested to
occur postnatally [5]. Major gene targets that are affected
in the ETV6/RUNX1 fusion involve genes for stem cell de-
velopment or lineage specification in hematopoiesis [6].
Such fusion in B-cell ALL leads to the activation of kinase
or alteration of transcriptional regulations [6].
Various techniques to screen and study chromosomal
aberrations in ALL have been developed in recent years.
Conventional cytogenetics is routinely used in the initial
assessment for the purpose of classification of specific
leukemia [7]. Complementary techniques to conventional
cytogenetics such as fluorescence in situ hybridization
(FISH), and reverse transcriptase - polymerase chain reac-
tion (RT-PCR) can be used as screening tools for ETV6/
RUNX1-positive patients [8]. FISH study is useful to iden-
tify specific translocation, but it is limited to the type ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Aberrations in 11 patients >1 Mb based on array-
CGH findings


















del(9)(p22.1 - p21.3) 2.4
del(14)(q22.2 - q23.1) 4.2
del(14)(q24.1 - q24.3) 6.4
del(15)q11.2 1.3
5 del(1)q31.1 - q31.2 4.0
del(1)q31.3 2.4
del(1)q42.2 - q43 4.8
del(3)p25.1 - p24.3 3.1
del(3)q26.1 5.6
del(4)q32.3 2.2
del(5)q21.1 - q23.3 26.1
del(6)p22.1 - p21.33 2.8
del(6)q15 - q22.2 27.6
del(6)q25.2 - q26 11.2
del(6)q25.3 2.5
del(8)q21.13 - q21.2 2.4
del(8)q23.2 - q23.3 4.9
del(12)p13.2 - p12.3 4.4
del(12)q21.1 2.9
del(12)q21.31 - q21.32 3.2
del(13)q21.31 - q21.33 3.1
del(13)q21.31 - q21.33 10.6
del(13)q31.1 - q31.3 9.1
6 amp(X)q11.1 - q28 91.0
del(6)q14.1 - q27 91.2
del(9)p21.3 1.5
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not genome-wide [9]. Array comparative genomic
hybridization (array CGH) has been applied to study copy
number alterations and genomic imbalances for evaluation
of patients with ALL [10]. Pathogenic chromosomal ab-
normalities have been reported in patients using the array-
based platform, suggesting the usefulness of this technique
for diagnostic services.
In the present study, eleven ETV6/RUNX1-positive
childhood ALL patients confirmed by RT-PCR were
investigated using high resolution array-based compara-




Based on the array-CGH data, a total of 155 genomic
aberrations (36 gains, 119 losses, excluding copy number
polymorphisms) were identified in all eleven patients, in-
cluding a patient (no. 4) with duplication of whole
chromosome 16. The aberrations ranged from 400 bp to
91.2 Mb. The number of aberrations per patient ranged
from 3 to 58, with mean of 14 aberrations per patient.
Of the 119 deletions detected, 39 were above 1 Mb and
80 were below 1 Mb. Of the 36 gains detected, 12 were
above 1 Mb and 24 were below 1 Mb. In agreement with
previous report, we found more deletions (76.8%) than
amplifications (23.2%) [11]. Five out of 11 patients (45%)
have a deletion of ETV6 gene. The detected aberrations
included previously reported loss/gains that are related
to ALL, such as 9p13.2 loss involving PAX5 in patient
no. 2 [12]; 9p21.3 loss involving CDKN2A in 4 patients
(nos. 3, 4, 6 and 7) and MLLT3 in patient no. 3 and 4.
Only one patient (no. 11) showed a 0.05 Mb deletion on
RUNX1 gene. Three patients (nos. 8, 9 and 10) showed
no gross genomic imbalances.
As summarized in Table 1, chromosome 2, 11, 16, 17,
19, 20, 21, and 22 did not have any aberrations above 1
Mb. The most common alterations above 1 Mb were de-
letion 6q (13%), 12p (12%) and 9p (8%), and amplifica-
tion 4q (6%) and Xq (4%). The gene annotations are
according to the University of California Santa Cruz
Genome Browser on Human March 2006 Assembly
(NCBI36/hg18).
FISH
All five patients (nos. 1, 3, 5, 6 and 9) showed positive
fusion signals of ETV6/RUNX1. Two patients (nos. 1
and 5) showed one fusion signal, but no green signal, in-
dicating a loss of ETV6 gene (Figure 1). Patient no.3
showed a single fusion signal and three red signals, indi-
cating a duplication of RUNX1 and a loss of ETV6 gene
in 55% interphase cells scored (Figure 1). Interestingly,
two fusion signals were identified in patient no. 6.
Table 1 Aberrations in 11 patients >1 Mb based on array-
CGH findings (Continued)
7 amp(10)q11.21 - q11.22 2.4
amp(15)q11.2 1.3
del(9)p21.3 3.1
8 No gross imbalances
9 amp(X)p22.31 1.6
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translocation (Figure 1).
The status of the ETV6 and RUNX1 genes in the
patients based on array-CGH and FISH findings are as
shown in Table 2.Discussion
Our data have demonstrated that the 244K oligonucleo-
tide array-CGH platform is a powerful tool to detect
additional copy number alterations in ETV6/RUNX1-
positive patients. A total of 155 aberrations were identi-
fied, including microdeletions as small as 400 bp. Many
known or potential genes related to leukemia were also
identified using this method. These data supported the
secondary leukemogenic model that additional aberra-
tions are necessary for leukemogenesis. According to
our array data, 5 out of 11 patients (45%) showed dele-
tion involving ETV6 gene from as small as 0.2 Mb to
19.4 Mb. We found more deletions (76.8%) than amplifi-
cations (23.2%), which is in agreement with a previous
study [11]. Among the deletions, 32.7% were larger than
1 Mb, while 33.3% of the amplifications were larger than
1 Mb.
Patient no. 2 harbored a 0.09 Mb deletion on 9p13.2
that involved the PAX5 gene. PAX5 is important in the
normal development of B cells, in which loss of a wild-
type PAX5 allele would cause differentiation arrest in
ALL [12]. Deletion of the tumor suppressor CDKN2A
gene located at 9p21.3 was found in 36% (4/11) of our
patients. The CDKN2A deletion is suggested to occur
more frequently in T-ALL than in precursor B-ALL [13].
The deletion is thought to vary by cytogenetic subgroup
and the prognostic value of the incidence is yet to be
determined [14]. One patient (no. 7) was found to have
a gross deletion (1.0 Mb) on 3p14.2 region that included
the FHIT gene, which is proposed as a putative tumor-
suppressor gene. The deletion on this particular gene
was found to be correlated with a low clinical remission
rate and poor overall survival [15-17].Several putative target genes within the commonly
gained region, including cryptic Xq duplications were
also found in patient no. 3 and 6, both females. The sizes
of the gains on the two patients were 2.1 Mb and 91
Mb, respectively. This result is discordant with the pre-
vious report that males are more common to harbor this
aberration [18]. This discrepancy may be explained by
the small sample size used in this study. It would be
interesting to study the expression level of ETV6/
RUNX1 proposed genes, namely the SPANX family
genes, on the X chromosome in our female's dataset.
Based on our FISH study on five childhood ALL patients,
all samples showed a positive ETV6/RUNX1 fusion signal.
Three patients (nos. 1, 3 and 5) showed concordant result
with array CGH for ETV6 gene deletion. FISH result for pa-
tient no. 3 showed three red signals, suggesting that there
was a duplication of the RUNX1 signal, but was not con-
firmed through the array findings. It has been reported that
DNA microarray may fail to detect the chromosomal ab-
normalities if the abnormal clones are present in fewer than
25% of the cell population [19].
Patient no. 6 showed a unique FISH profile where two
fusion signals of the ETV6/RUNX1 were detected.
Double ETV6/RUNX1 fusion signals were found in 25%
of ETV6/RUNX1 positive ALL patients [20]. Previous
studies have found that the additional ETV6/RUNX1 fu-
sion signal may have arisen from duplication of the der
(21)t(12;21) chromosome [21,22], duplication of ETV6/
RUNX1 fusion gene that was later translocated onto an-
other chromosome [22] or ider(21)(q10)t(12;21)(p12;
q22) [23]. In the study by Loncarevic and coworkers
(1999), gain of the der(21)t(12;21) chromosome was
found exclusively in the relapsed cases [21]. We were
not able to ascertain the origin of the extra ETV6/
RUNX1 fusion signal in our patient due to non-
availability of metaphase cytogenetics. It has however
been suggested that secondary changes such as the du-
plication of fusion signals may contribute to the process
of leukemogenesis [22].
Three of the patients, namely patient nos. 4, 10 and
11, had a relapse. Of the three, patient no. 4 had mul-
tiple gross deletions as large as 90.8 Mb, whereas patient
no. 11 had other gross imbalances larger than 1 Mb.
However, the array report for patient no. 10 showed no
gross imbalances larger than 1 Mb. We could not deter-
mine whether any subsequent aberrations happened
after the sample was taken which might trigger the re-
lapse event.
Conclusion
Our study indicates that high resolution oligonucleotide
array-CGH is an essential complementary tool in the in-
vestigation of the ETV6/RUNX1 positive ALL patients as
it helps to complement the findings of FISH and RT-
Figure 1 FISH in 4 patients. (a) Case no. 1 shows 1 red,1 residual red and 1 fusion signal, indicative of loss of ETV6; (b) Case no. 3 shows 3 red
and 1 fusion signal, indicative of extra RUNX1 and loss of ETV6; (c) Case no. 6 shows 2 fusion,1 red,1 residual red and 1 green signal; (d) Case no.
9 shows a typical FISH profile for t(12:21).
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tional cytogenetics which require cell culture and quality
metaphases for analysis. Indeed, array-CGH has revealed
additional aberrations which may have pathogenetic
implications. A larger cohort is however needed to com-
prehensively study the genetic diversity of our ETV6/
RUNX1- positive ALL cases.Materials and methods
Patients
Eleven ETV6/RUNX1-positive childhood ALL patients
(7 boys and 4 girls) with ages ranging from 2 to 11 years
old were selected for this study. All patients wereTable 2 Array-CGH and FISH findings in patients
Case No. Array CGH result Significant gene
1 Loss of 12p13 (ETV6), no loss on RUNX1 Loss of ETV6
2 Loss of 12p13 (ETV6); no gain on RUNX1 Loss of PAX5, ETV
3 Loss of 12p13 (ETV6); no gain on RUNX1 Loss of MLLT3, CD
4 Loss of ETV6 or RUNX1 was not found Loss of MYB, JAK
5 Loss of 12p13 (ETV6); no loss on RUNX1 Loss of ETV6
6 Loss of ETV6 or RUNX1 was not found Loss of MYB, MTA
7 Loss of 12p13 (ETV6); no gain on RUNX1 Loss of MTAP, CD
8 Loss of ETV6 or RUNX1 was not found Appears normal
9 Loss of ETV6 or RUNX1 was not found Appears normal
10 Loss of ETV6 or RUNX1 was not found Appears normal
11 Loss of 21q22 (RUNX1); no loss on ETV6 Loss of RUNX1
F = Fusion (ETV6-RUNX1 fusion); R = Red (normal RUNX1 gene); r = residual red (resdiagnosed as precursor B-ALL with CALLA positivity
based on their immuno-phenotyping report. The pres-
ence of ETV6/RUNX1 fusion gene in all cases was
ascertained by HemaVisionW Multiplex RT-PCR System
(Bio-Rad Laboratories, Hercules, CA) as part of the rou-
tine diagnostic procedure. The study was approved by
the Medical Research & Ethics Committee, Ministry of
Health Malaysia.
DNAs were extracted from bone marrow aspirates
using QIAGEN DNAeasy Blood Kit (Qiagen, Hilden,
Germany) according to manufacturer’s instruction. DNA
samples subjected to array CGH were of sufficient qual-
ity with A260/280 ratio >1.8 as measured by NanoDrop
ND-1000 UV–VIS spectrophotometer.s affected FISH result
Rr, 1F - 92%
6, KRAS NA
KN2A/B, MTAP, NOTCH1, BTG1, ETV6 3R, 1F - 55% 2R, 1F - 39%
2, MLLT3, CDKN2A/B, MTAP NA
Rr, 1F - 95%
P, CDKN2A/B, 2F, Rr, 1G - 60% Rr, 1F, 1G - 37%
KN2A/B, ETV6, FHIT NA
NA
Rr, 1G, 1F - 100%
NA
NA
idual RUNX1gene disrupted by the translocation); G = Green (ETV6 gene).
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Array-CGH analysis on the 11 patient samples was carried
out using Human Genome CGH 244A Microarray Kit
(Agilent Technologies, CA, USA) according to the manu-
facturer’s protocols. In brief, 1–3 μg of DNA from each pa-
tient and reference sample was subjected to restriction
digestion using AluI and RsaI restriction enzymes. The
reference DNA was commercially obtained from Promega
(Promega, Madison, WI) and was gender-matched accord-
ingly. The completion of the digestion for each sample was
analyzed using Bioanalyzer before the samples were labeled
using Cy3 and Cy5 for patient samples and reference sam-
ples, respectively. The yield, the degree of labeling, and the
specific activity of the samples were measured using Nano-
Drop before the two respective samples were combined.
The hybridization procedure was carried out at 37 °C for
40 hours and the slides were scanned using Agilent DNA
Microarray Scanner. The images from the array-CGH were
processed using Agilent Feature Extraction Software (ver-
sion 9.5.31). The data obtained were analyzed using DNA
Analytics v4.0.76 software (Agilent Technologies) with an
ADM-2 algorithm with threshold 6.0, and minimum adja-
cent 3 probes required to be gained or lost for a call to be
made. The array-CGH data for all samples have been
deposited in Gene Expression Omnibus and are accessible
through GEO series accession number GSE32897.FISH
Five patients with available suspension were selected for
FISH studies. The slides for FISH analysis were pre-
pared using cell suspension and were dried at 60°C
overnight. The Vysis LSI ETV6/RUNX1 ES dual-color
probe was used to identify the translocation pattern for
these samples. The probe was added to the slides, hybri-
dized on HyBrite and washed through a series of
washes. The slides were viewed under fluorescent
microscope, and at least 200 interphase nuclei were
analysed for their fusion signal.
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